Bawat Water Technologies

Nordic Solar A/S har her til morgen aflagt Q1 2023 regnskab. Insider salg i Scandinavian Medical Solutions. Bawat A/S offentliggjorde i tirsdags deres resultater for første kvartal 2023. Vi har netop offentliggjort vores opdaterede SaaS rapport. Hansa Biopharma’s vigtige partner inden for genterapiområdet, Sarepta Therapeutics, måtte i går gennem endnu en kursmæssig rutsjetur. Curasight har her til morgen aflagt regnskab for 1. kvartal.

This week, Bawat released its Q1 2023 results, which showed an order intake of SEK 9.3m. The company repeated its full-year 2023 guidance of an order intake in the range of SEK 40-60m.

Today, Bawat released its Q1 2023 result update, which showed an order intake of SEK 9.3m and revenue of SEK 4.2m. 

Late Wednesday, Bawat published its final audited 2022 annual report. In February, Bawat already announced its Q4 report with full-year numbers, implying that financials have been announced to the market. Read the full report here.

Shape Robotics er her til morgen ude med en investornyhed om selskabets ansættelse af nye bestyrelsesmedlemmer. Curasight indgår en eksklusiv partnerskabsaftale med Curium på Utrace i prostata cancer. WindowMaster har vundet en ny amerikansk projektkontrakt. Følg med i Green-Tech event i dag.

On 2 May 2023 , HC Andersen Capital and Inderes hosted a virtual live event focusing on small and midsized GreenTech companies in the Nordics. Despite the lower interest rates, rising CO2 prices, and a lot of political support, the green transition investment theme has overall been one of the sectors with the lowest returns based on share price performance this year.

Dagens aktienyheder med Hansa Biopharma der indgår samarbejde med franske Genethon, samt kommende events med Danske Bank og Green-Tech seminar.

Boozt har her til morgen offentliggjort regnskab for 1. kvartal 2023. NTG | Nordic Transport Group A/S: DSV regnskab. BankNordik har her til morgen offentliggjort et solidt regnskab for 1. kvartal 2023. InterMail Danmark har her til morgen aflagt H1 2022/23 regnskab. Bawat A/S meddelte i går kort før markedsluk, at selskabet har fået endelig godkendelse på Nefco-finansieringen på i alt SEK 25 mio. Scape Technologies A/S var i går aftes efter markedsluk ude med regnskabet for 2022.

Today, shortly before the market closed, Bawat announced its final approval from Nefco of a loan agreement and hence the decision to carry out directed share issues. Referring to Bawat’s financing plan communicated on 17 April 2023, the Nefco-financing has received final approval regarding the financing of SEK 25m divided into two tranches. Consequently, Bawat carries out two directed share issues with total proceeds of SEK 18.8m (before transaction costs) at a subscription price of SEK 1.60 per share.

BankNordik opjusterer. GreenMobility A/S har her til morgen udsendt Q1 handelsopdatering. Asetek har her til morgen udsendt foreløbige hovedtal for Q1 2023. Bawat A/S annoncerede i går eftermiddag, at selskabet har modtaget tegningstilsagn. I relation til InDex Pharmaceuticals AB meddelte Eli Lilly i sidste uge, at FDA ikke vil godkende selskabets ellers færdigudviklede produktkandidat mirikizumab. Re-Match melder her til morgen, at fabrikken i Herning genoptager deres fulde produktion.

Today, Bawat announced that the company has received subscription commitments for directed share issues of SEK 18.8m to match the first tranche of Nefco-financing and signed final term sheets with Nefco.

Dagens aktienyheder med nyheder fra Green Hydrogen Systems, Vestjysk Bank, Bawat, Shape Robotics, ExpreS2ion Biotechnologies, Qlife

Friday after the market closed, Bawat updated on its working capital situation and financing plan. The company estimates that it has sufficient working capital until the end of July 2023, and the financing plan regarding financing from NEFCO and the new share issue is still ongoing. Further information is expected to be announced in the near term.